Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib

Oncogene

Volumn 30, Issue 10, 2011, Pages 1183-1193

  Welti, J C ^a   Gourlaouen, M ^a   Powles, T ^b   Kudahetti, S C ^b   Wilson, P ^c   Berney, D M ^b   Reynolds, A R ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c Department of Medical Oncology ^*  (United Kingdom)

Author keywords

angiogenesis; growth factors; renal cancer; resistance; sunitinib

Indexed keywords

1 TERT BUTYL 3 [6 (3,5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 7 YL]UREA; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR; SUNITINIB; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CELL PROLIFERATION; DRUG ACTIVITY; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; KIDNEY CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

AGED; ANGIOGENESIS INHIBITORS; DRUG RESISTANCE, NEOPLASM; ENDOTHELIAL CELLS; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; IMMUNOBLOTTING; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PYRROLES; SIGNAL TRANSDUCTION; TISSUE ARRAY ANALYSIS;

EID: 79952538238     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.503     Document Type: Article

References (51)

1. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. (2003). SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2: 471-478.
2. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. (2003). Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111: 1287-1295. (Pubitemid 36554699)
3. Bergers G, Hanahan D. (2008). Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8: 592-603.
4. Britten CD, Kabbinavar F, Hecht JR, Bello CL, Li J, Baum C et al. (2008). A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. Cancer Chemother Pharmacol 61: 515-524. (Pubitemid 350275988)
5. Bryant DM, Stow JL. (2005). Nuclear translocation of cell-surface receptors: lessons from fibroblast growth factor. Traffic 6: 947-954. (Pubitemid 41309402)
6. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. (2005). Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8: 299-309. (Pubitemid 41443415)
7. Crawford Y, Kasman I, Yu L, Zhong C, Wu X, Modrusan Z et al. (2009). PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 15: 21-34.
8. Cross MJ, Claesson-Welsh L. (2001). FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci 22: 201-207. (Pubitemid 32244307)
9. Ebos JM, Lee CR, Kerbel RS. (2009). Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clin Cancer Res 15: 5020-5025.
10. Eguchi J, Nomata K, Kanda S, Igawa T, Taide M, Koga S et al. (1992). Gene expression and immunohistochemical localization of basic fibroblast growth factor in renal cell carcinoma. Biochem Biophys Res Commun 183: 937-944.
11. Eliceiri BP, Klemke R, Stromblad S, Cheresh DA. (1998). Integrin alphavbeta3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis. J Cell Biol 140: 1255-1263. (Pubitemid 28128883)
12. Ellis LM, Hicklin DJ. (2008). VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 8: 579-591.
13. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N et al. (2006). Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24: 25-35. (Pubitemid 46630490)
14. Faivre S, Demetri G, Sargent W, Raymond E. (2007). Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 6: 734-745. (Pubitemid 47338181)
15. Ferrara N. (2002). VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2: 795-803. (Pubitemid 37328914)
16. Ferrara N, Gerber HP, LeCouter J. (2003). The biology of VEGF and its receptors. Nat Med 9: 669-676. (Pubitemid 36749215)
17. Ferrara N, Hillan KJ, Gerber HP, Novotny W. (2004). Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3: 391-400. (Pubitemid 38618122)
18. Ferrara N, Kerbel RS. (2005). Angiogenesis as a therapeutic target. Nature 438: 967-974. (Pubitemid 43093963)
19. Fischer C, Jonckx B, Mazzone M, Zacchigna S, Loges S, Pattarini L et al. (2007). Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 131: 463-475. (Pubitemid 350007692)
20. Fukata S, Inoue K, Kamada M, Kawada C, Furihata M, Ohtsuki Y et al. (2005). Levels of angiogenesis and expression of angiogenesis-related genes are prognostic for organ-specific metastasis of renal cell carcinoma. Cancer 103: 931-942. (Pubitemid 40270069)
21. Giavazzi R, Sennino B, Coltrini D, Garofalo A, Dossi R, Ronca R et al. (2003). Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis. Am J Pathol 162: 1913-1926. (Pubitemid 36613049)
22. Gualandris A, Rusnati M, Belleri M, Nelli EE, Bastaki M, Molinari-Tosatti MP et al. (1996). Basic fibroblast growth factor over-expression in endothelial cells: an autocrine mechanism for angiogenesis and angioproliferative diseases. Cell Growth Differ 7: 147-160. (Pubitemid 26049823)
23. Hanahan D, Folkman J. (1996). Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364. (Pubitemid 26272076)
24. Huang D, Ding Y, Li Y, Luo WM, Zhang ZF, Snider J et al. (2010a). Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. Cancer Res 70: 1053-1062.
25. Huang D, Ding Y, Zhou M, Rini BI, Petillo D, Qian CN et al. (2010b). Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res 70: 1063-1071.
26. Joy A, Moffett J, Neary K, Mordechai E, Stachowiak EK, Coons S et al. (1997). Nuclear accumulation of FGF-2 is associated with proliferation of human astrocytes and glioma cells. Oncogene 14: 171-183. (Pubitemid 27068303)
27. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT et al. (2008). A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26: 127-132.
28. Kerbel R, Folkman J. (2002). Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2: 727-739. (Pubitemid 37328908)
29. Kerbel RS. (2008). Tumor angiogenesis. N Engl J Med 358: 2039-2049. (Pubitemid 351656458)
30. 0Brien S, Sennino B, Nakahara T et al. (2006). Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 116: 2610-2621. (Pubitemid 44511625)
31. Mavria G, Vercoulen Y, Yeo M, Paterson H, Karasarides M, Marais R et al. (2006). ERK-MAPK signaling opposes Rho-kinase to promote endothelial cell survival and sprouting during angiogenesis. Cancer Cell 9: 33-44. (Pubitemid 43069509)
32. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G et al. (2003). In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/ pharmacodynamic relationship. Clin Cancer Res 9: 327-337. (Pubitemid 36109749)
33. Meyer RD, Latz C, Rahimi N. (2003). Recruitment and activation of phospholipase Cgamma1 by vascular endothelial growth factor receptor-2 are required for tubulogenesis and differentiation of endothelial cells. J Biol Chem 278: 16347-16355. (Pubitemid 36799761)
34. Mohammadi M, Froum S, Hamby JM, Schroeder MC, Panek RL, Lu GH et al. (1998). Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. Embo J 17: 5896-5904. (Pubitemid 28474784)
35. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O et al. (2007). Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115-124. (Pubitemid 46089672)
36. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S et al. (2009). Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27: 3584-3590.
37. Nakatsu MN, Hughes CC. (2008). An optimized three-dimensional in vitro model for the analysis of angiogenesis. Methods Enzymol 443: 65-82.
38. Nanus DM, Schmitz-Drager BJ, Motzer RJ, Lee AC, Vlamis V, Cordon-Cardo C et al. (1993). Expression of basic fibroblast growth factor in primary human renal tumors: correlation with poor survival. J Natl Cancer Inst 85: 1597-1599. (Pubitemid 23304689)
39. O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW et al. (2003). SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101: 3597-3605. (Pubitemid 36857948)
40. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. (2006). VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol 7: 359-371.
41. Pardo OE, Latigo J, Jeffery RE, Nye E, Poulsom R, Spencer-Dene B et al. (2009). The fibroblast growth factor receptor inhibitor PD173074 blocks small cell lung cancer growth in vitro and in vivo. Cancer Res 69: 8645-8651.
42. Pepper MS, Ferrara N, Orci L, Montesano R. (1992). Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun 189: 824-831. (Pubitemid 23032448)
43. Pintucci G, Moscatelli D, Saponara F, Biernacki PR, Baumann FG, Bizekis C et al. (2002). Lack of ERK activation and cell migration in FGF-2-deficient endothelial cells. FASEB J 16: 598-600.
44. 0Era P, Ragnotti G. (1991). Basic fibroblast growth factor requires a long-lasting activation of protein kinase C to induce cell proliferation in transformed fetal bovine aortic endothelial cells. Cell Regul 2: 719-726.
45. 0Era P, Mitola S, Moroni E, Ronca R, Rusnati M. (2005). Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 16: 159-178. (Pubitemid 40616114)
46. Ravaud A, Hawkins R, Gardner JP, Von der Maase H, Zantl N, Harper P et al. (2008). Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial. J Clin Oncol 26: 2285-2291.
47. Relf M, LeJeune S, Scott PA, Fox S, Smith K, Leek R et al. (1997). Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 57: 963-969. (Pubitemid 27098025)
48. Rini BI, Atkins MB. (2009). Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol 10: 992-1000.
49. Schweigerer L, Neufeld G, Friedman J, Abraham JA, Fiddes JC, Gospodarowicz D. (1987). Capillary endothelial cells express basic fibroblast growth factor, a mitogen that promotes their own growth. Nature 325: 257-259. (Pubitemid 17049885)
50. Slaton JW, Inoue K, Perrotte P, El-Naggar AK, Swanson DA, Fidler IJ et al. (2001). Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma. Am J Pathol 158: 735-743. (Pubitemid 32158635)
51. Turner N, Grose R. (2010). Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 10: 116-129.